Skip directly to content

BMS-986094 (formerly INX-189)

on Thu, 09/13/2012 - 20:08

Last updated September 2012

Class/Type

Nucleotide polymerase inhibitor

Manufacturer/Sponsor(s)

Bristol-Myers Squibb

Dose

25 mg, 50 mg, 100 mg, 200 mg

Once-daily

Status

Discontinued due to toxicity

Population/Duration

Genotypes 2 and 3

Treatment-naive

12 weeks

Being studied with:

  • RBV
  • PEG-IFN/RBV
  • daclatasvir (NS5a inhibitor)

In January 2012, BMS purchased Inhibitex for approximately US$2.5 billion dollars, largely to get hold of INX-189 (now known as BMS-986094), a nucleotide in phase II. The drug was discontinued for toxicity after the death of a study participant in August of 2012. 


References: